Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2004

View Archived Issues

Novel NMDA antagonists may protect neurons from ischemia-induced cell death

Phase I/II trial of human papillomavirus vaccine

Genentech reviews Q2 developments

Endothelin receptor antagonist attenuates diabetes-induced endothelial lesions

Menarini reports a new class of NK2 antagonists with potential as analgesic agents

New 5-HT6 antagonist with improved pharmacokinetic properties designed at GSK

A cyanoguanidine-based prodrug identified as a clinical candidate by Leo scientists

Endo acquires North American rights to Rapinyl

New modafinil formulation shows promise for children with ADHD

New antidiabetic agents in early development at Bayer

Novel SGLT2 inhibitors prepared and tested at Kissei

Bayer scientists design new MKK4 and/or MKK7 inhibitors

New antiobesity agents disclosed by Bayer in a recent patent

Boehringer Ingelheim claims novel factor Xa inhibitors

New inhibitors of ICAM-1/LFA-1-mediated cell adhesion and their use

New cannabinoid CB1 antagonist for use in obesity, cognitive disorders, etc.

ProIX obtains development and marketing rights for novel PI-3K inhibitors

Antiretroviral effects of statins indicate potential in HIV infection

Viragen updates Multiferon progress

Liprostin successfully completes phase II study in peripheral vascular disease

Alimta approved for second-line treatment of advanced lung cancer

Canadian approval for phase I study of Proxinium

Sanofi-Aventis is world's third largest pharma company

European MAA submission for clofarabine for pediatric leukemias

Orphan drug status for HuMax-CD4

Kyorin and Merck conclude license agreement

Zeria targets launches after 2006

Novel back-up candidate with vasopressin antagonist activity identified at Yamanouchi

Results of efficacy and pharmacokinetic studies of an anxiolytic prodrug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...